Krystal Biotech stock (US5012681064): Hits all-time high near $316

Krystal Biotech shares reached an all-time high of $315.68, driven by strong financial performance and positive EPS streak, with gross margins over 94%.

Krystal Biotech stock surged to an all-time high of 315.68 USD recently, reflecting sustained growth in its genetic medicine portfolio, according to Investing.com. The commercial-stage biotech has delivered 11 or 12 consecutive quarters of positive EPS, bolstering investor confidence amid robust U.S. and international expansion for its lead product VYJUVEK.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Krystal Biotech, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: United States, global
• Key revenue drivers: VYJUVEK for DEB
• Home exchange/listing venue: Nasdaq (KRYS)
• Trading currency: USD

Krystal Biotech: core business model

Krystal Biotech is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet needs, primarily in the United States, per its overview on Simply Wall St. The firm's platform leverages herpes-simplex virus type 1 vectors to deliver functional genes directly to target tissues.

Its flagship product, VYJUVEK (beremagene geperpavec-svdt, or B-VEC), is approved for dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. This topical therapy addresses a critical gap in treatments for DEB patients.

Main revenue and product drivers for Krystal Biotech

VYJUVEK drives the majority of revenue, with strong U.S. sales growth and expanding ex-U.S. adoption, supported by high physician awareness, as noted in recent updates on TradingView. The company reported a market cap of €7.81 billion and TTM earnings of €192.18 million as of recent data.

Pipeline advancements include additional indications for genetic medicines, contributing to the stock's momentum toward all-time highs. Gross profit margins stand at an impressive 94.17%, underscoring operational efficiency.

Industry trends and competitive position

The biotech sector sees rising demand for gene therapies targeting rare diseases, where Krystal Biotech holds a differentiated position with its manufacturing capabilities and commercial traction in dermatology genetics. U.S. investors benefit from Nasdaq listing and exposure to innovative therapies amid growing FDA approvals for similar platforms.

Why Krystal Biotech matters for US investors

Listed on Nasdaq under KRYS, Krystal Biotech offers U.S. investors direct access to a leader in gene therapy for rare diseases, with revenue tied to the robust U.S. healthcare market. Its positive EPS streak and high margins signal profitability in a high-growth niche.

Conclusion

Krystal Biotech's stock has hit all-time highs on the back of strong product performance, consistent profitability, and pipeline potential. While the biotech space remains dynamic, the company's U.S.-centric focus and commercial success provide key data points for monitoring. Market conditions and clinical updates will shape near-term trading.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.